Fulcrum Therapeutics Inc (NAS:FULC)

$ 7.47 -0.03 (-0.4%) Market Cap: 464.29 Mil Enterprise Value: 238.89 Mil PE Ratio: 0 PB Ratio: 1.97 GF Score: 48/100

Q4 2023 Fulcrum Therapeutics Inc Earnings Call Transcript
Feb 27, 2024

$10.18 (+4.62%)

Earnings
Q3 2023 Fulcrum Therapeutics Inc Earnings Call Transcript
Nov 07, 2023

$4.29 (+19.50%)

Earnings
Q2 2023 Fulcrum Therapeutics Inc Earnings Call Transcript
Aug 03, 2023

$3.85 (+0.79%)

Earnings
Q1 2023 Fulcrum Therapeutics Inc Earnings Call Transcript
May 15, 2023

$3.64 (+11.31%)

Earnings
Q4 2022 Fulcrum Therapeutics Inc Earnings Call Transcript
Mar 09, 2023

$4.82 (-23.00%)

Earnings
Fulcrum Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Fulcrum Therapeutics Inc at Bank of America Biotech SMID Cap Conference Transcript
Dec 08, 2022
Fulcrum Therapeutics Inc at Credit Suisse Healthcare Conference Transcript
Nov 08, 2022
Q3 2022 Fulcrum Therapeutics Inc Earnings Call Transcript
Nov 08, 2022

$6.45 (+14.97%)

Earnings
Fulcrum Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022
Q2 2022 Fulcrum Therapeutics Inc Earnings Call Transcript
Aug 11, 2022

$7.57 (-2.45%)

Earnings
Fulcrum Therapeutics Inc To Review Initial FTX-6058 Data And Provide Program Update Call Transcript
Jun 10, 2022
Fulcrum Therapeutics Inc at Bank of America Healthcare Conference Transcript
May 12, 2022
Q1 2022 Fulcrum Therapeutics Inc Earnings Call Transcript
May 09, 2022

$7.66 (-11.24%)

Earnings
Fulcrum Therapeutics Inc To Discuss Unmet Need In FSHD, REACH Trial And Key Measures Of Disease Progression Call Transcript
Mar 24, 2022
Q4 2021 Fulcrum Therapeutics Inc Earnings Call Transcript
Mar 03, 2022

$11.7 (+5.41%)

Earnings
Fulcrum Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2022
Fulcrum Therapeutics Inc To Discuss Phase 1 Clinical Trial of FTX-6058 Call Transcript
Dec 06, 2021
Fulcrum Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 11, 2021
Q3 2021 Fulcrum Therapeutics Inc Earnings Call Transcript
Nov 04, 2021

$21.15 (+3.27%)

Earnings
Fulcrum Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Q2 2021 Fulcrum Therapeutics Inc Earnings Call Transcript
Aug 10, 2021

$18.77 (+125.33%)

Earnings
Fulcrum Therapeutics Inc Annual FSHD Society International Research Congress- Corporate Call Transcript
Jun 24, 2021
Fulcrum Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 13, 2021
Q1 2021 Fulcrum Therapeutics Inc Earnings Call Transcript
May 06, 2021

$10.58 (+5.06%)

Earnings
Q4 2020 Fulcrum Therapeutics Inc Earnings Call Transcript
Mar 04, 2021

$12.5 (-14.32%)

Earnings
Fulcrum Therapeutics, Inc. - Special Call Transcript
Dec 15, 2020
Q3 2020 Fulcrum Therapeutics Inc Earnings Call Transcript
Nov 10, 2020

$10.94 (+1.11%)

Earnings
Q2 2020 Fulcrum Therapeutics Inc Earnings Call Transcript
Aug 11, 2020

$8.9 (-48.01%)

Earnings
Fulcrum Therapeutics, Inc. - Special Call Transcript
Jun 10, 2020
Fulcrum Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020
Q1 2020 Fulcrum Therapeutics Inc Earnings Call Transcript
May 13, 2020

$16.48 (+10.53%)

Earnings
Q4 2019 Fulcrum Therapeutics Inc Earnings Call Transcript
Mar 05, 2020

$18.5 (+2.78%)

Earnings
Q3 2019 Fulcrum Therapeutics Inc Earnings Call Transcript
Nov 14, 2019

$7.64 (-3.29%)

Earnings

Fulcrum Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 12, 2023 / 12:30AM GMT

Release Date Price: $13.97 (+6.32%)

Transcript 8-K

Lalita Sundarrajan

Hi, everyone. Good afternoon, and welcome to the 41st Annual JPMorgan Healthcare Conference. My name is Lalita Sundarrajan, and I'm an associate here on the JPMorgan healthcare banking team. It's my absolute pleasure to introduce our speaker for today's presentation, CEO of Fulcrum Therapeutics, Robert Gould. He's joined on stage by CFO, Esther Rajavelu; and Chief Medical Officer, Santiago Arroyo. With that, Robert, I'll turn it over to you.

Robert J. Gould

Fulcrum Therapeutics, Inc. - Interim CEO & Director

Well, thank you very much, and thank you to JPMorgan for the opportunity to present to you this afternoon. What we'll be looking at today is the progress we've made over the last year at Fulcrum Therapeutics and also looking forward to some of the highlights of what we anticipate coming in 2023. As such, I'll be presenting forward-looking statements.

Fulcrum was started about 7 years ago with the vision of treating genetically defined diseases with small molecules to change the lives of patients with genetically defined diseases

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.